Log in |
Daphne Hompes MD, André D’Hoore MD, PhD, Eric Van Cutsem MD, PhD, Steffen Fieuws PhD, Wim Ceelen MD, PhD, Marc Peeters MD, PhD, Kurt Van der Speeten MD, PhD, Claude Bertrand MD, Hugues Legendre MD, Joseph Kerger MD
View full article HTML | View full article PDF | Download Citation
Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases. Complete cytoreductive surgery (CCRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) aims for locoregional disease control and long-term survival. Oxaliplatin is effective for treating advanced CRC. This study assesses the safety and efficacy of CCRS with HIPEC with oxaliplatin for patients with PC of CRC.
A Belgian prospective multicenter registry was performed to monitor perioperative morbidity and assess mortality, disease-free survival (DFS), and overall survival (OS).
Forty-eight consecutive patients underwent CCRS (R0/1) with HIPEC (male/female ratio 17/31, median age 60 years, range 24–76 years). Median PC index was 11 (range 1–22). Median operation time was 460 (range 125–840) min, with a median blood loss of 475 (range 2–6,000) ml. Thirty-day mortality was 0%. Complication rate (any grade) was 52.1%. Anastomotic leakage occurred in 10.4% of patients, bleeding in 6.3%, and bowel perforation in 2.1%. Median hospital stay was 20 (range 5–65) days. At median follow-up of 22.7 (range 3.2–55.7) months, OS was 97.9% [95% confidence interval (CI) 86.1–99.7] at 1 year and 88.7% (95% CI 73.6–95.4) at 2 years. DFS at 1 year was 65.8% (95% CI 52.3–76.2) and 45.5% (95% CI 34.3–55.9) at 2 years. Median time until recurrence was 19.8 months (95% CI 12–upper limit not defined). Only after dichotomizing PC index was a significant difference in OS found between low and high PC index.
CCRS followed by HIPEC with oxaliplatin for PC from CRC can be implemented with acceptable morbidity. Long-term DFS and OS can be achieved in selected patients.
Go to Issue Contents
Add this article to your Personal Archive
Effective January 2013, there will be a processing fee of $50 USD for each initial new submission of an Annals article, excluding editorials. Submitted new manuscripts will not enter the review process until the submission fee has been paid. . There will be no processing fee associated with resubmitted manuscripts.
HIGHLIGHTED VIDEO OF THE MONTH
Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES) by R. A. Cahill MD, FRCS, S. Perretta MD, J. Leroy MD, B. Dallemagne MD, and J. Marescaux MD, FRCS, FACS. Annals of Surgical Oncology. Volume 15, Number 10, DOI: 10.1245/s10434-008-9952-8
Annals of Surgical Oncology is copyrighted by the Society of Surgical Oncology
© Springer Healthcare Ltd. A part of Springer Science+Business Media